CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Rasagiline mesylate

Rasagiline mesylate

Last Updated: March 10, 2009

Result type: Reports

Project Number: SF0161-000

Product Line: Reimbursement Review

Generic Name: Rasagiline mesylate

Brand Name: Azilect

Manufacturer: Teva Pharmaceuticals Industries Ltd.

Therapeutic Area: Parkinson?s disease

Indications: Parkinson’s disease

Submission Type: Request For Advice

Project Status: Complete

Rasagiline mesylate

Files